Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crisantaspase recombinant
- Development stage
- Approved
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous
01
Overview
Crisantaspase recombinant (JZP-458) is a recombinant form of the enzyme L-asparaginase derived from *Erwinia chrysanthemi*. It is produced using the Pelican Expression Technology platform (formerly Pfenex Expression Technology), which utilizes *Pseudomonas fluorescens* for high-quality protein production. The drug is specifically indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to *E. coli*-derived asparaginase products. By depleting circulating levels of L-asparagine—an amino acid that neoplastic cells are unable to synthesize efficiently due to low asparagine synthetase expression—crisantaspase recombinant inhibits protein synthesis and induces apoptosis in leukemic cells. It was developed by Jazz Pharmaceuticals to address manufacturing challenges and supply shortages associated with the naturally derived Erwinia asparaginase (Erwinaze).
- Brand names
- RylazeEnrylaze
- Other names
- recombinant Erwinia asparaginaseRC-Pasparaginase erwinia chrysanthemi (recombinant)-rywn
Beyond the preview
Go deeper on crisantaspase recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crisantaspase recombinant.